氯吡格雷联合低分子肝素钙对急性加重期慢性肺源性心脏病的临床效果
2016-10-21张民赵锋
张民 赵锋
【摘要】 目的:探討应用氯吡格雷(Clopidogrel)联合低分子肝素钙(LMWH)对慢性肺源性心脏病(肺心病,chronic pulmonary heart disease)急性加重期的临床疗效。方法:将诊断为慢性肺心病加重期的患者80例,随机分成治疗组40例和对照组40例。对照组采用控制感染、止咳、化痰、平喘、解痉、持续低流量吸氧、保持呼吸道通畅、强心、利尿、抗心律失常等常规治疗;治疗组在常规治疗基础上加用皮下注射低分子肝素钙和口服氯吡格雷片治疗。同步检测两组患者治疗前后血浆凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、凝血酶时间(TT)、纤维蛋白原(Fb)因子和肺功能(FEV1),并加以分析比较。结果:(1)治疗后治疗组Fb值明显低于对照组(P<0.01),PT、APTT、TT和FEV1明显高于对照组,差异均有统计学意义(P<0.05)。(2)治疗组和对照组临床有效率分别为80.0%、65.0%,两组比较差异有统计学意义(字2=4.815,P<0.05)。结论:氯吡格雷联合低分子肝素钙治疗慢性肺源性心脏病具有降低痰液黏稠度、抗炎及抗过敏作用,并且还可以降低血小板凝集,使肺部血流量增加,起到改善肺心病的作用,对治疗慢性肺源性心脏病特别是加重期,临床效果十分显著,值得推广应用。
【关键词】 氯吡格雷; 低分子肝素钙; 肺源性心脏病
中图分类号 R541.5 文献标识码 A 文章编号 1674-6805(2016)6-0018-03
The Clinical Effect of Clopidogrel Combined with Low Molecular Weight Heparin for Acute Exacerbation of Chronic Pulmonary Heart Disease/ZHANG Min,ZHAO Feng.//Chinese and Foreign Medical Research,2016,14(6):18-20
【Abstract】 Objective:To evaluate the Clopidogrel combined with Low Molecular Weight Heparin(LMWH) on acute exacerbation of chronic pulmonary heart disease.Method:80 cases with acute exacerbation of chronic pulmonary heart disease were randomly divided into the treatment group and the control group,40 cases in each group.The control group was taken conventional treatment of infection control,relieving cough,reducing sputum,relieving spasm and asthma,persistent low flow oxygen,maintain airway patency,strong heart,diuresis,anti arrhythmia,the treatment group was treated with subcutaneous injection of Low Molecular Weight Heparin and oral Clopidogrel therapy based on routine treatment. plasma prothrombin time(PT),activated partial thromboplastin time(APTT),thrombin time(TT),fibrinogen(Fb) and pulmonary function(FEV1) were simultaneous detected in two groups before and after treatment.Result:Fb in the treatment group was obviously lower than that of the control group after treatment(P<0.01),PT,APTT,TT and FEV1 were higher than those in the control group,there were significant difference(P<0.05).The clinical effect in the treatment group was 80.0%,the control group was 65.0%,there was statistically significant in two groups(P<0.05).Conclusion:Clopidogrel combined with Low Molecular Heparin Calcium can reduce sputum viscosity and anti-inflammatory and anti allergic effect,and can reduce platelet aggregation,decrease the blood viscosity,for the treatment of chronic pulmonary heart disease,especially exacerbation,the clinical effect is significant,worthy of promotion and application.
【Key words】 Clopidogrel; Low Molecular Weight Heparin Calcium; Chronic pulmonary heart disease
First-authors address:Shengli Petroleum Administration Bureau Geophysical Prospecting Hospital,Dongying 257086,China
doi:10.14033/j.cnki.cfmr.2016.6.009
慢性肺源性心脏病(chronic pulmonary heart disease)是临床慢性阻塞性肺部疾病的晚期症状之一,属于一种不可逆性全身多脏器功能障碍性疾病。其急性加重期由于血液呈高凝状态,极易导致微血栓形成,据报道死亡患者的尸检中肺小动脉血栓发现率为90%左右,且均为由于肺小动脉原位血栓形成,导致肺组织、肺动脉血管慢性病变引起肺组织功能异常[1]。慢性肺源性心脏病是呼吸系统的一种常见病,高原、寒冷地区及农村地区发病率较高,发病年龄大多在40岁以上,并随着年龄增高而增高[2]。慢性肺心病加重期是临床常见危重病症,内科常规应用抗生素、解痉平喘、止咳化痰、纠正水电解质紊乱、持续吸氧等综合治疗,治疗效果不理想。……
